Mouse double minute antagonist Nutlin-3a enhances chemotherapy-induced apoptosis in cancer cells with mutant p53 by activating E2F1

[1]  J. Garibal,et al.  Activation of p53 by MDM2 antagonists has differential apoptotic effects on Epstein–Barr virus (EBV)-positive and EBV-negative Burkitt's lymphoma cells , 2009, Leukemia.

[2]  O. Myklebost,et al.  Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[3]  L. Vassilev,et al.  Nongenotoxic activation of the p53 pathway as a therapeutic strategy for multiple myeloma. , 2005, Blood.

[4]  Sudhir Agrawal,et al.  Stabilization of E2F1 protein by MDM2 through the E2F1 ubiquitination pathway , 2005, Oncogene.

[5]  Marina Konopleva,et al.  MDM2 antagonists induce p53-dependent apoptosis in AML: implications for leukemia therapy. , 2005, Blood.

[6]  L. Vassilev,et al.  p53 Activation by Small Molecules: Application in Oncology , 2005 .

[7]  Pankaj Oberoi,et al.  Small molecule inhibitors of HDM2 ubiquitin ligase activity stabilize and activate p53 in cells. , 2005, Cancer cell.

[8]  Hong Yang,et al.  Activation of p53 by MDM2 antagonists can protect proliferating cells from mitotic inhibitors. , 2005, Cancer research.

[9]  G. Tortora,et al.  Chemosensitization by antisense oligonucleotides targeting MDM2. , 2005, Current cancer drug targets.

[10]  A. Levine,et al.  MDM2 is a central node in the p53 pathway: 12 years and counting. , 2005, Current cancer drug targets.

[11]  M. Dai,et al.  Inhibition of MDM2-mediated p53 Ubiquitination and Degradation by Ribosomal Protein L5* , 2004, Journal of Biological Chemistry.

[12]  D. Ginsberg,et al.  Up-regulation of Bcl-2 Homology 3 (BH3)-only Proteins by E2F1 Mediates Apoptosis* , 2004, Journal of Biological Chemistry.

[13]  L. Vassilev,et al.  In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2 , 2004, Science.

[14]  Bohdan Wasylyk,et al.  p53-independent functions of MDM2. , 2003, Molecular cancer research : MCR.

[15]  I. Screpanti,et al.  Differential regulation of E2F1 apoptotic target genes in response to DNA damage , 2003, Nature Cell Biology.

[16]  H. Endo,et al.  Apaf-1 Is a Mediator of E2F-1-induced Apoptosis* , 2002, The Journal of Biological Chemistry.

[17]  J. Nevins,et al.  Selective induction of E2F1 in response to DNA damage, mediated by ATM-dependent phosphorylation. , 2001, Genes & development.

[18]  F. Christians,et al.  E2Fs regulate the expression of genes involved in differentiation, development, proliferation, and apoptosis. , 2001, Genes & development.

[19]  B. Pützer,et al.  Role of the p53-homologue p73 in E2F1-induced apoptosis , 2000, Nature Genetics.

[20]  David I. Smith,et al.  Role for the p53 homologue p73 in E2F-1-induced apoptosis , 2000, Nature.

[21]  N. L. La Thangue,et al.  Apoptotic and Growth-Promoting Activity of E2F Modulated by MDM2 , 2000, Molecular and Cellular Biology.

[22]  W. Kaelin,et al.  MDM2 Suppresses p73 Function without Promoting p73 Degradation , 1999, Molecular and Cellular Biology.

[23]  B. Wasylyk,et al.  p53 mediated death of cells overexpressing MDM2 by an inhibitor of MDM2 interaction with p53 , 1999, Oncogene.

[24]  R. Honda,et al.  Association of p19ARF with Mdm2 inhibits ubiquitin ligase activity of Mdm2 for tumor suppressor p53 , 1999, The EMBO journal.

[25]  D. Banerjee,et al.  Role of E2F-1 in chemosensitivity. , 1998, Cancer research.

[26]  J. Niland,et al.  The MDM2 gene amplification database. , 1998, Nucleic acids research.

[27]  D. Lane,et al.  p53 protein stability in tumour cells is not determined by mutation but is dependent on Mdm2 binding , 1997, Oncogene.

[28]  Z. Yuan,et al.  Role for E2F in DNA damage-induced entry of cells into S phase. , 1997, Cancer research.

[29]  J. Piette,et al.  Mdm2: keeping p53 under control , 1997, Oncogene.

[30]  J. Cleveland,et al.  E2F-1 cooperates with topoisomerase II inhibition and DNA damage to selectively augment p53-independent apoptosis , 1997, Molecular and cellular biology.

[31]  Tony Kouzarides,et al.  Stimulation of E2F1/DP1 transcriptional activity by MDM2 oncoprotein , 1995, Nature.

[32]  W. Sellers,et al.  Interaction between the retinoblastoma protein and the oncoprotein MDM2 , 1995, Nature.

[33]  J. Nevins,et al.  E2F1 overexpression in quiescent fibroblasts leads to induction of cellular DNA synthesis and apoptosis , 1995, Journal of virology.

[34]  W. Kaelin,et al.  Deregulated transcription factor E2F-1 expression leads to S-phase entry and p53-mediated apoptosis. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[35]  A. Levine,et al.  p53 and E2F-1 cooperate to mediate apoptosis. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[36]  J. Nevins,et al.  Expression of transcription factor E2F1 induces quiescent cells to enter S phase , 1993, Nature.

[37]  W. El-Deiry,et al.  p53-independent increase in E2F-1 expression enhances the cytotoxic effects of etoposide and of adriamycin. , 1999, International journal of oncology.